Prescient Therapeutics Welcomes US FDA Allowance of Investigational New Drug Application for PTX-100 Phase 2 Clinical Trial | ASX:PTX, OTC:PSTTF

Proactive InvestorsDec 22 18:11 ET

Prescient Therapeutics Appoints Experienced Pharmaceuticals Executive James McDonnell as CEO | ASX:PTX, OTC:PSTTF

Proactive InvestorsDec 16 20:29 ET

Prescient Therapeutics CEO Yatomi-Clarke Steps Down; Will Remain Available as a Consultant

Investing.com Sep 11 19:55 ET

Prescient Therapeutics "an ASX-listed Oncology Drug Developer With a Big FY25 Ahead", Says Pitt Street Research

Investing.com Sep 4 19:54 ET

Prescient Therapeutics Ltd: Appendix 4E and 2024 Annual Report

Aug 25 19:54 ET · Announcements

Prescient Therapeutics Refines Phase 2 PTX-100 Trial Design for Greater Success

Investing.com Jul 30 23:35 ET